Moxifloxacin Stada® (Moxifloxacin)

Moxifloxacin is a broad‑spectrum fluoroquinolone that targets bacterial DNA replication in respiratory and skin infections.

• Community‑acquired pneumonia: eradicates causative bacteria, facilitating clinical recovery.
• Acute bacterial sinusitis: reduces sinus inflammation by eliminating the infecting organisms.
• Acute bacterial exacerbation of chronic bronchitis: improves lung function by clearing bacterial load.
• Skin and soft‑tissue infections: resolves infection and promotes wound healing.

• Moxifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA supercoiling and replication. By binding to these targets, it prevents bacterial DNA synthesis and transcription, leading to bacterial cell death and a bactericidal effect against susceptible Gram‑positive and Gram‑negative organisms.

Moxifloxacin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, often self‑limiting.
• Headache: transient cranial discomfort.
• Dizziness: occasional light‑headedness.
• Rash: mild skin erythema.
• Elevated liver enzymes: transient laboratory changes.

Serious or Rare Side Effects

• Tendon rupture: sudden pain and loss of function, especially in the Achilles.
• QT interval prolongation: cardiac rhythm disturbances.
• Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome.
• Clostridioides difficile colitis: severe diarrhea with abdominal pain.
• Peripheral neuropathy: numbness or tingling in extremities.
• Hepatotoxicity: significant liver injury with jaundice.

Before prescribing Moxifloxacin, clinicians should assess patient history and potential risks.

• Assess cardiac history: avoid in patients with known QT prolongation.
• Review tendon health: caution in those with recent tendon injury or steroid use.
• Evaluate renal function: dose adjustment may be required in severe impairment.
• Monitor for hypersensitivity: discontinue if severe allergic reactions occur.
• Avoid in pregnancy and lactation unless benefits outweigh risks: safety data are limited.
• Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Moxifloxacin can interact with several drug classes, affecting efficacy or safety.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce absorption, separate dosing by at least 2 hours.
• Warfarin: may increase INR, requiring close monitoring.
• Drugs that prolong QT interval (e.g., macrolides, fluoroquinolones): heightened risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely)

• CYP1A2 inhibitors (e.g., fluvoxamine): may increase plasma levels.
• Theophylline: potential for increased theophylline toxicity.
• Corticosteroids: may raise risk of tendon rupture.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): increased risk of central nervous system effects.